Literature DB >> 8272217

Effect of captopril on renal extraction of renin, angiotensin II, atrial natriuretic peptide and vasopressin, and renal vein renin ratio in patients with arterial hypertension and unilateral renal artery disease.

E B Pedersen1, H Eiskjaer, B Madsen, H Danielsen, M Egeblad, C B Nielsen.   

Abstract

Plasma renin activity (PRA) and plasma concentrations of angiotensin II (AngII), atrial natriuretic peptide (ANP) and arginine vasopressin (AVP) were determined in the abdominal aorta and the renal veins before and 1 h after peroral ingestion of captopril 25 mg in 29 patients with arterial hypertension and unilateral renal artery stenosis or occlusion, in order to study the effect of ACE inhibition on single-kidney extraction ratio (ER) of PRA, AngII, ANP, and AVP, and on renal vein renin ratio (RVRR). PRA was increased, AngII and ANP were reduced, and AVP unchanged after captopril. On the affected side the negative ER or PRA (-1.03) and AngII (-0.28) and the positive ER of ANP (0.25) and AVP (0.14) were not significantly changed by captopril. On the non-affected side ER of AngII and ER of ANP were significantly reduced (ER of AngII, 0.41-0.00, ER of ANP, 0.29-0.17), but ER of PRA and ER of AVP were unchanged. RVRR was not significantly changed by captopril. RVRR was greater than 1.5 in 79% of the patients before captopril, in 82% after captopril, and in 93% either before or after captopril. It is concluded that captopril reduces ER of AngII and ER of ANP on the non-affected side but not on the affected side in unilateral renal artery disease with hypertension, and that the use of RVRR both before and after captopril improves the predictive value of RVRR with regard to the diagnosis of unilateral renal artery disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8272217

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  20 in total

1.  High pulse pressure is not associated with abnormal activation of the renin-angiotensin-aldosterone system in repaired aortic coarctation.

Authors:  T A L Pedersen; E B Pedersen; K Munk; V E Hjortdal; K Emmertsen; N H Andersen
Journal:  J Hum Hypertens       Date:  2014-08-28       Impact factor: 3.012

2.  Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment.

Authors:  Janni M Jensen; Frank H Mose; Anna-Ewa O Kulik; Jesper N Bech; Robert A Fenton; Erling B Pedersen
Journal:  World J Nephrol       Date:  2015-07-06

3.  Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.

Authors:  Frank H Mose; Janni M Jensen; Safa Therwani; Jesper Mortensen; Annebirthe B Hansen; Jesper N Bech; Erling B Pedersen
Journal:  Br J Clin Pharmacol       Date:  2015-06-05       Impact factor: 4.335

4.  Eprosartan modulates the reflex activation of the sympathetic nervous system in sodium restricted healthy humans.

Authors:  Henrik Vase; Thomas G Lauridsen; Jesper N Bech; Erling B Pedersen
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

5.  Abnormal function of the vasopressin-cyclic-AMP-aquaporin2 axis during urine concentrating and diluting in patients with reduced renal function. A case control study.

Authors:  Erling B Pedersen; Ingrid M Thomsen; Thomas G Lauridsen
Journal:  BMC Nephrol       Date:  2010-10-05       Impact factor: 2.388

6.  Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.

Authors:  Frank Holden Mose; Thomas Larsen; Janni Majgaard Jensen; Annebirthe Bo Hansen; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

7.  Abnormal increase in urinary aquaporin-2 excretion in response to hypertonic saline in essential hypertension.

Authors:  Carolina Cannillo Graffe; Jesper Nørgaard Bech; Thomas Guldager Lauridsen; Henrik Vase; Erling Bjerregaard Pedersen
Journal:  BMC Nephrol       Date:  2012-03-27       Impact factor: 2.388

8.  Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial.

Authors:  Thomas Larsen; Frank H Mose; Jesper N Bech; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2013-07-26       Impact factor: 2.388

9.  Increased renal sodium absorption by inhibition of prostaglandin synthesis during fasting in healthy man. A possible role of the epithelial sodium channels.

Authors:  Thomas G Lauridsen; Henrik Vase; Jørn Starklint; Carolina C Graffe; Jesper N Bech; Søren Nielsen; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2010-10-28       Impact factor: 2.388

10.  Cardiovascular effects of cholecalciferol treatment in dialysis patients--a randomized controlled trial.

Authors:  Frank H Mose; Henrik Vase; Thomas Larsen; Anne S P Kancir; Renata Kosierkiewic; Bartlomiej Jonczy; Annebirthe B Hansen; Anna E Oczachowska-Kulik; Ingrid M Thomsen; Jesper N Bech; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2014-03-24       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.